Immune Design Corp Company Profile (NASDAQ:IMDZ)

Immune Design Corp trades on the NASDAQ under the ticker symbol "IMDZ."

Immune Design Corp (NASDAQ:IMDZ) announced its quarterly earnings results on Tuesday, March, 7th. The company reported ($0.57) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.57). The business had revenue of $2.06 million for the quarter, compared to analysts' expectations of $1.34 million. Immune Design Corp had a negative net margin of 415.05% and a negative return on equity of 50.92%. View Immune Design Corp's Earnings History.

3 analysts have issued 1 year price targets for Immune Design Corp's shares. Their predictions range from $18.00 to $18.00. On average, they anticipate Immune Design Corp's share price to reach $18.00 in the next year. View Analyst Ratings for Immune Design Corp.

Here are some recent quotes from research analysts about Immune Design Corp stock:

• 1. According to Zacks Investment Research, "Immune Design’s primary candidates, CMB305 and G100, are being evaluated for solid tumor, and merkel cell carcinoma (MCC) and sarcoma, respectively. Immune Design has a number of candidates in its pipeline but none is in late-stage development and consequently several years away from commercialization. An unfavorable result from any of the studies may force the company to postpone or discontinue the studies. The company is highly dependent on its collaboration partners for top-line growth which increases its vulnerability. The company’s shares have underperformed the Medical-Drugs industry year to date. Loss estimates have widened lately ahead of the Q1 earnings results. However, the company expects to provide significant clinical data produced by both lead product candidate in both monotherapy and in combination trials to support their potential registration paths towards commercialization in 2017." (5/18/2017)
• 2. Jefferies Group LLC analysts commented, "Though 2016 was relatively quiet, we believe the year of trial execution helped establish a foundation to build upon in 2017, with accumulating CMB305/ LV305 OS data and randomized '305 and '100 datasets potentially helping confirm the agents' promise and potential regulatory path. With data at AACR, ASCO, ESMO, and ASH this year, we see catalysts to draw greater attention to IMDZ and drive upside for shares; increasing tgt to $16. Financials: 4Q OpEx was $16.6M, consisting of $12.0M R&D vs. our $11.6M est and $4.4M G&A, vs. our $4.2M est. Their net loss was $14.5M compared to our $13.8M est. The company ended the quarter with $110.4M in cash, which includes $30.3M from follow-on financing. IMDZ believes their cash position should provide a runway until 2H18. Updated follow-up data for CMB305 and LV305 in soft tissue sarcoma (STS) suggests survival tracking well ahead of historical data." (3/8/2017)

Some companies that are related to Immune Design Corp include Myokardia (MYOK), NanoString Technologies (NSTG), Bellicum Pharmaceuticals (BLCM), PDL BioPharma (PDLI), Celldex Therapeutics (CLDX), Seres Therapeutics (MCRB), Otonomy (OTIC), BioSpecifics Technologies Corp. (BSTC), BioTime (BTX), Lion Biotechnologies (LBIO), Pacific Biosciences of California (PACB), Agenus (AGEN), Aurinia Pharmaceuticals (AUPH), Advaxis (ADXS), ChemoCentryx (CCXI), Corbus Pharmaceuticals Holdings (CRBP), GlycoMimetics (GLYC) and Ocular Therapeutix (OCUL).

Immune Design Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include Versant Venture Management LLC (8.68%), ProQuest Associates IV LLC (7.68%), Victory Capital Management Inc. (7.62%), FMR LLC (1.75%), Vanguard Group Inc. (1.50%) and JPMorgan Chase & Co. (0.95%). Company insiders that own Immune Design Corp stock include Carlos V Paya, Franklin M Berger, Group L P Column, Lewis W Coleman, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design Corp.

Immune Design Corp's stock was sold by a variety of institutional investors in the last quarter, including Weiss Multi Strategy Advisers LLC, JPMorgan Chase & Co., Morgan Stanley, Oxford Asset Management and Bank of New York Mellon Corp. Company insiders that have sold Immune Design Corp stock in the last year include Carlos V Paya, Franklin M Berger, Lewis W Coleman and Stephen R Brady. View Insider Buying and Selling for Immune Design Corp.

Immune Design Corp's stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Renaissance Technologies LLC, Vanguard Group Inc., Wells Fargo & Company MN, Trexquant Investment LP, Dimensional Fund Advisors LP, Bank of America Corp DE and TIAA CREF Investment Management LLC. Company insiders that have bought Immune Design Corp stock in the last two years include Group L P Column, Lewis W Coleman and Stephen R Brady. View Insider Buying and Selling for Immune Design Corp.

Shares of Immune Design Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Immune Design Corp stock can currently be purchased for approximately $8.00.